Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, single-center prospective phase II study to evaluate the
efficacy and safety of rechallenge chemotherapy in the third or later-line treatment in
patients with advanced colorectal cancer. The primary end point is progression free survival
(PFS). A total of 42 patients who failed with oxaliplatin, irinotecan and fluorouracil in
previous treatment and could not receive the target therapy presently are planned for
recruitment. For patients with metastatic colorectal cancer who met admission criteria,
oxaliplatin- or irinotecan-based chemo regimen could be used and evaluation was repeated
every 6 weeks. The treatment continues until the disease progression or the untolerable
adverse reaction.